DOWNLOAD and share the WHITE PAPER now The current array of healthcare reforms hasn’t produced a single reimbursement model that can replace our reliance on a fee-for-service (FFS)...
In earlier posts on the new frontier of Molecular Diagnostic testing, I’ve discussed the need for identifying and classifying tests as well as the opportunity and challenges this new technology...
“Changing the future of claims processing.” That’s how ACO News reported McKesson Episode Management’s™ recent release of 22 new episodes based on the PROMETHEUS...
A dramatic rise in spending on molecular diagnostic (MDx) tests, coupled with an inability to identify specific MDx tests submitted on claims, led Palmetto GBA, to initiate the Palmetto MolDX...
Molecular Diagnostics (MDx), the next wave of innovation in healthcare technology, is arriving. Exciting, challenging, transformational, hopeful, complex, alarming, terrifying and expensive are all...
Why Doctor Ratings Are Misleading - Richard Gunderman - The Atlantic rtag.co/Xfbg
Medical devices for kids are often only tested on adults | Reuters rtag.co/XfbH #medtech #wearables
Doctors Overlook Lucrative Procedures When Naming Unwise Treatments - Kaiser Health News rtag.co/XfbU
CBO: Obamacare Cost $104B Less Than Feb. Estimate: Video - Bloomberg rtag.co/Xfbq #ACA
What's the impact of ACA on medication costs? IMS Health report offers some clues rtag.co/Xfbd
Cost and Quality Improvement
Personalized Medicine/Molecular Diagnostics (MDx)
Point-of-Care Decision Management
Provider Network Management
Waste, Abuse and Fraud Prevention
Fredric Leary, MD
Jacqueline Mitus, MD
Douglas Moeller, MD
David Nace, MD
Emad Rizk, MD
Better Thinking for Better Health